EnVVeno Medical Reports Interim Venous Ulcer Healing Data From SAVVE U.E. Pivotal Trial For VenoValve To Be Presented At Society For Vascular Surgery 2024 Annual Meeting

6/21/24 8:39:01 AM ET

$NVNO

Medical/Dental Instruments

Health Care

Get the next $NVNO alert in real time by email

91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved

100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed

89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or Improved

No Ulcer Recurrences

Company on Track to File Application Seeking VenoValve FDA Approval in Q4 2024

Get the next $NVNO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVNO

Date	Price Target	Rating	Analyst

More analyst ratings

$NVNO
Financials

Live finance-specific insights

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A
11/20/24 8:30:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application
11/19/24 8:15:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
- Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w
9/19/22 8:05:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care

$NVNO
Press Releases

Fastest customizable press release news feed in the world

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A
11/20/24 8:30:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application
11/19/24 8:15:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial mid-2025Ended the quarter with $48.4 million cash and investments on hand sufficient to fund operations beyond expected regulatory approval of the VenoValve and start of the enVVe pivotal trial IRVINE, CA / ACCESSWIRE / October 31, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today reported financial results for the third quarter 2024."We
10/31/24 8:35:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care

EnVVeno Medical Reports Interim Venous Ulcer Healing Data From SAVVE U.E. Pivotal Trial For VenoValve To Be Presented At Society For Vascular Surgery 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for
$NVNO

$NVNO
Financials

Live finance-specific insights

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

$NVNO
Leadership Updates

Live Leadership Updates

$NVNO
SEC Filings

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

SEC Form DEF 14A filed by enVVeno Medical Corporation

Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation

SEC Form 10-Q filed by enVVeno Medical Corporation

$NVNO
Press Releases

Fastest customizable press release news feed in the world

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

$NVNO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

SEC Form SC 13G filed by enVVeno Medical Corporation

$NVNO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Alavi Hamed sold $51,837 worth of shares (8,334 units at $6.22) and exercised 8,334 shares at a strike of $3.59 (SEC Form 4)

SEC Form 4 filed by Glynn Craig

SEC Form 4 filed by Alavi Hamed

$NVNO
Market Insights

Live Market Insights

Market-Moving News for June 21st

EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surgery 2024 Annual Meeting.